Pasithea Therapeutics shares jumped more than 220% in early trading after the company said its wholly-owned Pasithea Clinics subsidiary was approved to provide esketamine nasal spray Spravato for treatment-resistant depression in adults.
The company said it has begun offering the treatment in its Knightsbridge, London, location.
Pasithea said esketamine is safe and effective, but due to some risks associated with the drug, patients treated in outpatient settings must be enrolled in a specific program.